Regulation of IGFBP-3 expression in breast cancer cells and uterus by estradiol and antiestrogens: correlations with effects on proliferation: a review.
This paper reviews actions of antiestrogens on IGF physiology, and discusses the potential significance of the recent observations that (i) effects of antiestrogens on the uterus are correlated with their effects on uterine IGF-I and IGFBP-3 gene expression, and that (ii) the potent antiestrogen and growth inhibitor ICI 182,780 induces autocrine production of IGFBP-3 by estrogen receptor-positive breast cancer cells, while the growth stimulatory action of estradiol is associated with suppression of IGFBP-3 expression.
Hung
H
H
Department of Medicine, McGill University, Montreal, Quebec, Canada.
Pollak
M
M
D001943:Breast Neoplasms / Q000378:metabolism*; D004958:Estradiol / Q000494:pharmacology*; D004965:Estrogen Antagonists / Q000494:pharmacology*; D005260:Female; D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000096:biosynthesis* / Q000235:genetics; D013629:Tamoxifen / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D014599:Uterus / Q000187:drug effects / Q000378:metabolism*
D004965:Estrogen Antagonists; D018972:Insulin-Like Growth Factor Binding Protein 3; D013629:Tamoxifen; D004958:Estradiol